For cancer patients, following the initial shock of their diagnosis, thoughts quickly turn to estimating how much precious time they have left with family and friends or whether certain treatments could prolong their life.
Mainz Biomed, a molecular genetics diagnostic company specializing in the early detection of cancer, announced a collaborative agreement with Thermo Fisher Scientific Inc. through its subsidiary Life Technologies Corporation.
